Key statistics
As of last trade, Immunitybio Inc (26CA:BER) traded at 2.70, 22.96% above the 52 week low of 2.20 set on Jan 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.64 |
---|---|
High | 2.75 |
Low | 2.64 |
Bid | 2.57 |
Offer | 2.78 |
Previous close | 2.63 |
Average volume | 5.94k |
---|---|
Shares outstanding | 730.16m |
Free float | 159.91m |
P/E (TTM) | -- |
Market cap | 2.45bn USD |
EPS (TTM) | -0.867 USD |
Data delayed at least 15 minutes, as of Mar 13 2025 19:08 BST.
More ▼
Press releases
- ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
- ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
- ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
- FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
- ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
- ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
- ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
- ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
More ▼